Dkk1, a common Wnt antagonist, was shown to be elevated in patients with CKD-associated bone and mineral disorder and neutralization of Dkk1 by a monoclonal antibody was shown to prevent osteogenic trans-differentiation of VSMCs, VC, and renal osteodystrophy [24]. Here, DKK1 is linked to renal osteodystrophy.